tirzepatide glp 1 | GLP1 | Medical Weight Loss weekly GLP Procedure Helps Prevent Weight Regain

doi: 10.2337/diacare.26.3.784 100 KarlDPhilis-TsimikasADarsowTLorenziGKellmeyerTLutzKet al

Short- vs Long-acting GLP-1RAs and Evidence for Tachyphylaxis for Effects on Gastric Emptying GLP-1RAs have been divided into short-acting (eg, exenatide twice a day and lixisenatide) or long-acting (eg, liraglutide, dulaglutide, exenatide QW, semaglutide), based on whether their plasma concentrations return to near-zero levels between subcutaneous (SC) administrations or remain pharmacologically effective over at least 24 hours

Although meaningful reductions in glycemia and body weight have been observed, it remains unclear whether these co-agonists produce superior reductions in body weight and HbA1c relative to optimized GLP-1R agonists alone in these patient populations [52,53]

The strong clinical profile and versatile administration options have established semaglutide as a leading product type in the GLP-1 receptor agonist market